New Medicines to Protect Kidneys from Sudden Damage
Inhibitors of Thromboinflammation for Acute Kidney Injury
['FUNDING_SBIR_1'] · FUNCTION THERAPEUTICS, INC. · NIH-11087659
This project looks at new medicines that could help prevent or treat sudden kidney damage in people who are at risk.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FUNCTION THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11087659 on ClinicalTrials.gov |
What this research studies
Acute kidney injury (AKI) is a serious problem where kidney function suddenly declines, often after major surgery, severe infections like COVID-19, or certain cancer treatments. Currently, there are no approved drugs to prevent this dangerous condition. This project explores a new type of medicine, called parmodulins, which works by calming down inflammation and blood clotting in the body. Researchers believe these medicines could be very helpful in protecting kidneys from injury and are working to optimize them for this purpose.
Who could benefit from this research
Good fit: Ideal candidates would be patients at high risk for acute kidney injury, such as those undergoing major surgery, hospitalized with severe infections, or receiving certain anti-cancer therapies.
Not a fit: Patients who do not have a risk of acute kidney injury or who already have established chronic kidney disease may not directly benefit from this specific preventative approach.
Why it matters
Potential benefit: If successful, this could lead to the first approved drugs to prevent acute kidney injury, significantly improving patient outcomes and reducing the risk of chronic kidney disease.
How similar studies have performed: This approach involves a new class of molecules that have shown promising results in laboratory and animal models for related conditions, suggesting a novel but supported direction.
Where this research is happening
MILWAUKEE, UNITED STATES
- FUNCTION THERAPEUTICS, INC. — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DOCKENDORFF, CHRISTOPHER — FUNCTION THERAPEUTICS, INC.
- Study coordinator: DOCKENDORFF, CHRISTOPHER
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.